Q-omics provides the consensus-scored SYT8 profile across patient tissues and cancer cell-line models. SYT8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SYT8 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SYT8 RNA expression shows 12,600 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where SYT8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT8 survival associations across molecular data types. SYT8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT8 RNA expression–survival associations across cancer types. High SYT8 expression shows unfavorable associations in ACC, KIRC, LIHC, COAD and SKCM, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SYT8 RNA expression.
This table summarizes SYT8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SYT8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT8 shows lower tumor expression in HNSC and BRCA and higher tumor expression in COAD, THCA, STAD and UCEC. The HNSC box plot shows higher SYT8 RNA expression in normal versus tumor tissue (log2 FC = −1.708, t-test p < 0.001).
This table shows molecular features associated with SYT8 in patient tissues and cancer cell lines. In patient samples, SYT8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
